The related factors of endometrial cancer induced by obesity

doi:10.3760/cma.j.issn.1673-422X.2015.10.020

Abstract

Abstract: Large amounts of clinical studies and epidemiological data have confirmed that obesity is closely related to the development and progression of endometrial cancer. The mechanism of the endometrial cancer may be involved estrogen, insulin, insulinlike growth factor, leptin, adiponectin, resistin fat factor, inflammatory factors and so on.

Key words: Obesity, Endometrial neoplasms, Estrogens, Insulin, Adipokines

Zhang Ying, Sheng Xiugui. The related factors of endometrial cancer induced by obesity[J]. Journal of International Oncology, 2015, 42(10): 789-792.

References

［1］ Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 19992010［J］. JAMA, 2012, 307(5): 491-497. ［2］ Cheng H, Liu P, Zhang F, et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 is highly responsive to mTOR inhibition［J］. Cancer Res, 2014, 74(1): 15-23. ［3］ Mu N, Zhu Y, Wang Y, et al. Insulin resistance: a significant risk factor of endometrial cancer［J］. Gynecol Oncol, 2012, 56(125): 751-757. ［4］ Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation implications for novel treatment strategy［J］. Gynecol Oncol, 2010, 116（1）: 92-98. ［5］ Kohda M, Hoshiya H, Katoh M, et al. Frequent loss of imprinting of IGF2 and MEST in lung adernocarcinoma［J］. Mol Carcinog, 2001, 31(4): 184-191. ［6］ Hayashi K, Carpenter KD, Spencer TE. Neonatal estrogen exposure disrupts uterine development in the postnatal sheep［J］. Endocrinology, 2004, 145(7): 3247-3257. ［7］ McGrath M, Lee IM, Buring J, et al. Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk［J］. Gynecol Oncol, 2011, 120(2): 174-178. ［8］ Otvos LJr, Haspinger E, La Russa F, et al. Design and development of a peptidebased adiponectin receptor agonist for cancer treatment［J］. BMC Biotechnol, 2011, 11: 90. ［9］ Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a casecontrol study in Greece［J］. J Clin Endocrinol Metab, 2003, 88(3): 993-997. ［10］ Ashizawa N, Yahata T, Quan J, et al. Serum leptinadiponectin ratio and endometrial cancer risk in postmenopausal female subjects［J］. Gynecol Oncol, 2010, 119(1): 65-69. ［11］ Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer［J］. Buicghim Biophys Acta, 2010, 1804(3): 581-591. ［12］ Kitta Y, Takano H, Nakamura T, et al. Low adiponectin levels predict late instent restenosis after bare metal stenting in native coronary［J］. Int J Cardiol, 2008, 131(1): 78-82. ［13］ Birmingham JM, Busik JV, Hansensmith FM, et al. Novel mechanism for obesityinduced colon cancer progression［J］. Cancinogenesis, 2009, 30(4): 690-697. ［14］ Ranhouni K, Sigmund CD, Haynes WG, et al. Hypothalamic ERK mediates the anorectic and thermogenic sympathetic effects of leptin［J］. Diabetes, 2009, 58(3): 536-542. ［15］ Brown KA, McInnes KJ, Hunger NI, et al. Subcellular localization of cyclic AMPresponsive element binding proteinregulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women［J］. Cancer Res, 2009, 69(13): 5392-5399. ［16］ Luhn P, Dallal CM, Weiss JM, et al. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial［J］. Cancer Epidemiol Biomarkers Prev, 2013, 22(7): 1304-1312. ［17］刘婷婷, 张淑春, 高维萍. 血清瘦素和胰岛素生长因子Ⅱ与子宫内膜癌的相关性研究［J］. 中华妇幼临床医学杂志, 2013, 9(5): 651-652. ［18］李婷, 周奇, 王国增, 等. 抵抗素对人子宫内膜癌细胞增殖黏附及侵袭的影响［J］. 同济大学学报: 医学版, 2011, 32(5): 46-51. ［19］ Hlavna M, Kohut L, Lipkova J, et al. Relationship of resistin levels with endometrial cancer risk［J］. Neoplasma, 2011, 58(2): 124-128. ［20］ Lee JH, Bullen JW Jr, Stoyneva VL, et al. Circulating resistin in lean, obese, and insulin resistant mouse models: lack of association with insulinemia and glycemia［J］. Am J Physiol Endocrinol Metab, 2005, 288(3): E625-E632. ［21］ Malo E, Ukkola O, Jokela M, et al. Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish Health 2000 survey［J］. Metab Syndr Relat Disord, 2011, 9(3): 203-210. ［22］ Colotta F, Allavena P, Sica A, et al. Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability［J］. Carcinogenesis, 2009, 30(7): 1073-1081. ［23］ Clendenen TV, Koenig KL, Arslan AA, et al. Factors associated with inflammation markers, a crosssectional analysis［J］. Cytokine, 2011, 56(3): 769-778.

[1]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[2]	Fan Mengsi, Lu Yaping, Yan Li. Analysis of clinicopathologic features of false negative sentinel lymph nodes in patients with endometrial cancer [J]. Journal of International Oncology, 2023, 50(5): 274-279.
[3]	Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun. Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer [J]. Journal of International Oncology, 2022, 49(12): 724-728.
[4]	Xu Qiuyue, Ma Xianmei, Yue Qi. Immunotherapy for endometrial carcinoma based on molecular typing [J]. Journal of International Oncology, 2022, 49(11): 700-704.
[5]	Deng Bo'er, Kong Weimin. Epigenetic research progress of endometrial cancer [J]. Journal of International Oncology, 2021, 48(3): 184-188.
[6]	He Zhefeng, Pei Tiemin, Meng Qinghui. IGF2BP1 and cancer [J]. Journal of International Oncology, 2021, 48(2): 92-95.
[7]	Huang Yuting, Wang Chao. Anti-tumor effect of berberine hydrochloride combined with epirubicin and cisplatin on advanced endometrial carcinoma [J]. Journal of International Oncology, 2020, 47(9): 530-534.
[8]	Wang Xue, Ji Guoxin, Ji Chao, Yang Xingsheng. Effects of metformin on prognosis of type Ⅰ endometrial carcinoma patients complicated with type 2 diabetes mellitus [J]. Journal of International Oncology, 2020, 47(7): 404-408.
[9]	Zhao Xiaoling, Kong Weimin. Current status of basic and clinical research on metformin in endometrial cancer [J]. Journal of International Oncology, 2020, 47(7): 440-443.
[10]	Zhou Luqiu, Liu Xianxi, Li Yan, Mao Xiguang. Analysis of prognostic risk factors of type Ⅰ endometrial cancer [J]. Journal of International Oncology, 2020, 47(6): 346-350.
[11]	Luo Chuncui, Yuan Chaoyan, Chen Qingfen. GOLPH3 regulates proliferation and apoptosis of endometrial carcinoma cells through PI3K/AKT/GSK3β signal [J]. Journal of International Oncology, 2020, 47(2): 65-69.
[12]	FU Cai-Hong, ZHANG Bao-Ying, YUAN Wen-Zhen, GUAN Quan-Lin. Research progress of obesity and prognosis of breast neoplasms [J]. Journal of International Oncology, 2017, 44(8): 700-703.
[13]	LI Mei-Yan. Clinical significance of detection of HE4, OPN and uPA in the diagnosis of endometrial carcinoma [J]. Journal of International Oncology, 2017, 44(5): 351-355.
[14]	Wan Lijuan, Chen Mingwei. Relationship between insulin resistance related factors and colon cancer stem cells [J]. Journal of International Oncology, 2017, 44(10): 790-793.
[15]	Gao Wuyuan, Wang Lihua. Role of insulinlike growth factors family in endometrial cancer [J]. Journal of International Oncology, 2017, 44(10): 794-797.